|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Targeted therapies in gastric cancer and future perspectives显示文摘Advanced gastric cancer(AGC) is associated with a high mortality rate and, despite multiple new chemotherapy options, the survival rates of patients with AGC remains poor. After the discovery of targeted therapies, research has focused on the new treatment options for AGC. In the last two decades, many targeted molecules were developed against AGC. Currently, two targeted therapy molecules have been approved for patients with AGC. In 2010, trastuzumab was the first molecule shown to improve survival in patients with HER2-positive AGC as part of a first-line combination regimen. In 2014, ramucirumab was the second targeted molecule to improve survival rates and was suggested as treatment for patients with AGC who had progressed after firstline platinum plus fluoropyrimidine with or without anthracycline chemotherapy. Ramucirumab was the first targeted therapy acting as a single agent in patients with advanced gastroesophageal cancers. Although these two molecules were introduced into clinical use, many other promising molecules have been tested in phase Ⅰ-Ⅱ trials. It is obvious that in the near future many different targeted therapies will be in use for treatment of AGC. In this review, the current status of targeted therapies in the treatment of AGC and gastroesophageal junction tumors, including HER(2-3) inhibitors, epidermal growth factor receptor inhibitors, tyrosine kinase inhibitors, antiangiogenic agents, c-MET inhibitors, mammalian target of rapamycin inhibitors, agents against other molecular pathways fibroblast growth factor, Claudins, insulin-like growth factor, heat shock proteins, and immunotherapy, will be discussed. | Ozan Yazici M Ali Nahit Sendur Nuriye Ozdemir Sercan Aksoy | 2016 | World Journal of Gastroenterology2016，22，2： | 11 |
| 2 | Hepatitis C virus reactivation in cancer patients in the era of targeted therapies显示文摘The purpose of this review is to summarize the evidence of hepatitis C reactivation in cancer patients in the era of targeted therapies.Targeted therapies are novel therapeutics frequently used in cancer patients.During treatment with targeted therapies,viral replication is one of the major problems that can occur.The PubMed database,ASCO,and ASCO Gastrointestinal Cancer Symposium abstracts were searched up until September 15,2013 using the following search keywords:'targeted therapies,rituximab,alemtuzumab,brentuximab,hepatitis,hepatitis C reactivation,tyrosine kinase inhibitors,imatinib,mammalian target of rapamycin(mTOR)inhibitors,everolimus,anti-HER therapies,trastuzumab,pertuzumab,lapatinib,antiepidermal growth factor receptor therapies,cetuximab,panitumumab,and ipilimumab'.Papers considered relevant for the aim of this review were selected by the authors.The data about rituximab-induced hepatic flare in hepatitis C virus(HCV)positive patients is controver-sial.However,there is the possibility of life-threatening hepatic flare that can develop after HCV ribonucleic acid(HCV-RNA)viral load increases.Routine followup of liver function tests should be advised.Especially in high-risk patients,such as those with baseline chronic active hepatitis and cirrhosis,and where there are plans to administer rituximab concomitantly with corticosteroids,it is advised to have close follow-up of HCV viral load.The data is insufficient to make accurate statements about the association of alemtuzumab therapy and HCV reactivation.However,alemtuzumab may cause deep immunosuppression.Due to this,it is better to follow up with liver function tests and HCV RNA levels during alemtuzumab therapy.Brentuximab has effects on antibody dependent cellular toxicity and may decrease humoral immunity.Thus,we believe that during brentuximab treatment of HCV infected patients,clinicians may encounter hepatitis C reactivation.There have been no reported cases of hepatitis C reactivation with imatinib therapy.However,there are many reports of hepatitis B reactivation with imatinib treatment.Based on the evidence of hepatitis B reactivation with imatinib and the effects of imatinib on immune system functions,we suggest that imatinib therapy might be a risk factor for HCV reactivation.Anti-human epidermal growth factor receptor 2 therapies are not associated with hepatic flare in HCV infected patients.Post-transplant studies reported that mTOR was safely administered to patients with active hepatitis C without causing hepatic flare.Cetuximab and panitumumab have not been associated with HCV reactivation.Two cases of HCV infected melanoma were safely treated with ipilimumab without any HCV reactivation or hepatic flare.Targeted therapies are a new and emerging area of oncology treatment modalities.While treating HCV infected cancer patients,clinicians should be mindful of the immunosuppressive properties of targeted therapies.Further randomized trials are needed to establish algorithms for this issue. | Ozan Yazici Mehmet Ali Nahit ?endur Sercan Aksoy | 2014 | World Journal of Gastroenterology2014，20，22： | 5 |
| 3 | Control Strategies for Battery Energy Storage for Wind Farm Dispatching显示文摘 | SERCAN T MESUT E B ALEXQ H | 2009 | IEEE Transaction on Energy Conversion2009，24，3： | 1 |
| 4 | Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin显示文摘 | Sercan Aksoy Mehmet Ali Nahit Sendur Kadri Altundag | 2013 | Medical Oncology2013，，2： | 1 |
| 5 | Optimal contxol of bat- tery energy storage for wind farm dispatching显示文摘 | SERCAN T MESUT E B SUBHASHISH B | 2010 | IEEE Transaetions on Power Systems2010，25，3： | 1 |
| 6 | A novel model of retinopathy of prematurity in normobaric hyperoxic conditions显示文摘AIM:To examine changes in retinal vasculature after treatment with different oxygen concentrations from common retinopathy of prematurity(ROP) models and to determine a novel and practical ROP model.METHODS:A sample of 14 newborn Sprague-Dawley rats was used.The study group(n=7) was exposed to95%oxygen for 4h per day followed by normoxic laboratory conditions for 20 h.This cycle was repeated for 14 d.The control group(n=7) was subjected to normobaric normoxic conditions.On postnatal day 14(P14),the two groups were placed in room air for 7d.On P21,the two groups were examined using indirect ophthalmoscopy.All eyes were enucleated for immunofluorescence(IF) staining of the vasculature of retinas and analysis of vascular endothelial growth factor(VEGF),hypoxia inducible factor-1 alpha(HIF-1α),placental growth factor(PLGF) in vitreous humor,and then the rats were sacrificed by decapitation.All procedures were repeated using another litter of 14 pups.RESULTS:In the study group and under normobaric hyperoxic conditions,retinal neovascularization and peripheral avascular retina were determined in 85%of the rats through indirect ophthalmoscopic examination.Also IF staining of retina of the study group showed retarded peripheral vascular growth.The difference between the two groups for VEGF,HIF-1α and PLGF concentrations of vitreous humor was statistically significant(P=0.003,0.007,0.027 respectively).CONCLUSION:Fluctuating oxygen concentrations are primarily responsible for retinal neovascularization.Our new ROP model is practical and applicable for all retinal neovascularization studies,considering the laboratory procedures. | Taner Ozgurtas Sercan Tekin Fatih Yesildal Umut Karaca Fevzi Nuri Aydin Muhammed Talha Ugurlu Mehmet Ozler Hakan Durukan | 2016 | International Journal of Ophthalmology(English edition)2016，9，9： | 1 |
| 7 | Validation of battery energy storage control for wind farm dispatching显示文摘 | SERCAN T MESUT E B SUBHASHISH B | 2010 | IEEE2010，10，4： | 1 |
| 8 | Rule-based control of battery energy storage for dispatching intermittent renewable sour- ces显示文摘 | SERCAN T MESUT E B SUBHASH1SH B | 2010 | IEEE Trans Sustainable Energy2010，25，3： | 1 |
| 9 | Rule-based control of battery energy storage for dispatching intermittent renewable sources显示文摘 | SERCAN Teleke MESUT E BARAN | 2010 | IEEE Trans Sustainable Energy2010，25，3： | 1 |
| 10 | Collaborative Networks and Technology Clusters- The Case of Nanowire显示文摘 | Sercan Ozcan Nazrul Islam | 2014 | Technological Forecasting and Social Change2014，82，1： | 1 |
| 11 | Collaborative Networks and Tech- nology Clusters-the Case of Nanowire显示文摘 | Sercan Ozcan Nazrul Islam | 2014 | Technological Fore- casting and Social Change2014，82，1： | 1 |
| 12 | The clinical value of the novel cauterization procedure for the inferior turbinate artery during turbinate surgery显示文摘 | Rasit Midilli Sercan Gode Bulent Karci Mustafa Orhan Canan Saylam | 2012 | European Archives of Oto-Rhino-Laryngology2012，，6： | 1 |
| 13 | Beta-catenin mutations are not observed in chronic myeloid leukemia 显示文摘 | Sercan Z Pehlivan M Gokturk D | 2009 | Tumori2009，95，6： | 1 |
| 14 | Optimal control of battery energy storage for wind farm dispatching显示文摘 | Sercan Teleke Mesut E Baran Subhashish Bhattacharya | 2010 | IEEE Transactions on Energy Conversion2010，25，3： | 1 |
| 15 | Optimal control of battery energy storage for wind farm dispatching显示文摘 | Sercan T Mesut E B Subhashish B | | 0，，3： | 1 |
| 16 | Optima control of battery energy storage for wind farm dispatching显示文摘 | Teleke Sercan Baran Mt E Bhattacharya Subhashish | 2010 | IEEE Transactions on Energy Conver- sion2010，25，3： | 1 |
| 17 | Control strategies for battery energy storage for wind farm dispatching显示文摘 | Sercan T Mesut E B Alex Q H | 2009 | IEEE Transactions on Energy Conversion2009，24，3： | 1 |
| 18 | Biosorption potential of the waste biomaterial obtained from Cucumis melo for the removal of Pb24 ions from aqueous media:equilibrium,kinetic,thermodynamic and mechanism analysis显示文摘 | Sibel T A Sercan A Tugba A | 2012 | Chemical Engineering Journal2012，18，： | 1 |
| 19 | Arthroscopie treatment of symptomatic type D medial plica显示文摘 | Mustafa U Mehmet A Sercan A | 2008 | International Orhopaedics2008，32，： | 1 |
| 20 | Optimal control of battery energy storage for wind farm dispatching显示文摘 | Sercan T Mesut E B Alex Q H | | 0，，03： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员